SCHEMBL6844773

SCHEMBL6844773

CC(C)(C)OC(=O)N1CCN(c2cccc(C(F)(F)F)c2CC(=O)c2cccc(CCc3cncc(C(=O)O)c3)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.38
TTR P02766 1/20 0.38
GPR119 Q8TDV5 4/20 0.38
LIPG Q9Y5X9 1/20 0.37
GBA1 P04062 1/20 0.37
ENPP2 Q13822 1/20 0.37
SLC2A1 P11166 1/20 0.36
RORC P51449 1/20 0.36
MET P08581 1/20 0.36
CKS1B P61024 1/20 0.35
SKP1 P63208 1/20 0.35
SKP2 Q13309 1/20 0.35
PDK2 Q15119 1/20 0.35
SCD O00767 1/20 0.35
SCD5 Q86SK9 1/20 0.35
SOS1 Q07889 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
RBP4 P02753 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844796 0.94 PTK2 (0.40) ACHEGPR119LIPGSLC2A1MET
SCHEMBL6844775 0.88 LIPG (0.41) ACHEGPR119LIPGGBA1SLC2A1
SCHEMBL6844774 0.87 KDR (0.40) ACHETTRGPR119GBA1ENPP2
SCHEMBL6844798 0.81 LIPG (0.39) ACHEGPR119LIPGMETPDK2
SCHEMBL6844814 0.79 KDR (0.41) GPR119METSOS1RBP4
SCHEMBL6848352 0.79 ALDH1A1 (0.40) LIPGMETSCDSCD5SOS1
SCHEMBL6844776 0.74 KDR (0.40) ACHEGPR119LIPGGBA1MET
SCHEMBL6848356 0.74 ALDH1A1 (0.43) LIPGMETSCDSCD5
SCHEMBL6846512 0.71 PTPN11 (0.40) ACHELIPGMETSCDSCD5
SCHEMBL6844794 0.70 MAP3K20 (0.39) ACHEMETSCDSCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ACHE 2730/4885TTR 3487/4885GPR119 646/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA ACHE 2730/4885TTR 3487/4885GPR119 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.